Latest Articles

Publication Date
Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab - Physician's Weekly

Survival Outcomes in Advanced Endometrial Cancer with Lenvatinib plus Pembrolizumab Physician's Weekly

Published: Feb. 4, 2025, 11:09 a.m.
Judge Indicates 40 Hair Relaxer Lawsuits Over Uterine Cancer, Endometrial Cancer and Ovarian Cancer Will Be Selected for Early Trial Program - AboutLawsuits.com

Judge Indicates 40 Hair Relaxer Lawsuits Over Uterine Cancer, Endometrial Cancer and Ovarian Cancer Will Be Selected for Early Trial Program AboutLawsuits.com

Published: Feb. 3, 2025, 9:15 p.m.
Endometrial Cancer and Mental Health: Challenges and Finding Support - Healthline

Endometrial Cancer and Mental Health: Challenges and Finding Support Healthline

Published: Feb. 3, 2025, 5:51 p.m.
Potential biomarkers and immune infiltration linking endometriosis with recurrent pregnancy loss based on bioinformatics and machine learning.

Endometriosis (EMs) is a chronic inflammatory disease characterized by the presence of endometrial tissue in the non-uterine cavity, resulting in dysmenorrhea, pelvic pain, and infertility. Epidemiologic data have suggested the …

Published: Feb. 3, 2025, midnight
(PDF) Radiotherapy improves stress urinary incontinence but impairs pelvic floor function in endometrial cancer patients: a prospective cohort study - ResearchGate

(PDF) Radiotherapy improves stress urinary incontinence but impairs pelvic floor function in endometrial cancer patients: a prospective cohort study ResearchGate

Published: Feb. 2, 2025, 4:08 a.m.
Retrospective Data Highlight FRα and B7-H4 As Potential ADC Targets in Endometrial Cancer - OncLive

Retrospective Data Highlight FRα and B7-H4 As Potential ADC Targets in Endometrial Cancer OncLive

Published: Feb. 1, 2025, 12:11 a.m.
Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer - OncLive

Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer OncLive

Published: Feb. 1, 2025, 12:11 a.m.
Transfer of the Oral Gonadotropin-Releasing Hormone Receptor Antagonist Relugolix Into Breast Milk of Healthy Lactating Women.

Relugolix is an oral gonadotropin-releasing hormone receptor antagonist that suppresses sex steroid hormones and is approved as monotherapy for prostate cancer and as a fixed-dose combination with estradiol/norethindrone for the …

Published: Feb. 1, 2025, midnight
The effect of chronic inflammation on female fertility.

Inflammation has key biological roles in the battle against pathogens, and additional key processes in development and tissue homeostasis. However, when inflammation becomes chronic it can become a serious medical …

Published: Feb. 1, 2025, midnight
PPP2R1A Mutations Associated With Prolonged OS in High-Risk Endometrial Cancer - OncLive

PPP2R1A Mutations Associated With Prolonged OS in High-Risk Endometrial Cancer OncLive

Published: Jan. 31, 2025, 8:48 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!